Download Press Releases
- 399 kBPress Releases
- 15.11.07
SIRS-Lab wins Innovation Award
Jena, November 2007 SIRS-Labs proprietary technology incorporated in VYOO and LOOXSTER resulted from the close R&D network of the company. Together with the University Hospital Jena and the University of Applied Science Jena, the company developed these assets which received the federal Innovation Award of Thuringia.
read more » - 05.09.07
New weapon against sepsis: SIRS-Lab launches DNA-based test for fast pathogen detection
SIRS-Lab launches VYOO, a novel DNA-based test for the detection of sepsis pathogens. Within 6 hours, key-information for a successful antibiotic therapy is provided. VYOO combines precision, short time-to-results, and easy handling.
read more » - 04.09.07
Step by step - SIRS-Lab donates 1000 for sepsis research
A 24 hours walk and every kilometre counts: Dr. Peter Bauer, a committed scientist in Sepsis research, took the challenge of a 100 km trip to raise donations for Sepsis research.
read more » - 21.03.07
SIRS-Lab: Expert service for gene expression studies
Quality internationally accepted After only five years, SIRS-Lab has successfully established itself as the commercial provider of gene expression studies. In this fast-paced field, SIRS-Lab counts on the know how of an interdisciplinary team which possesses more than one hundred man-years of expertises in biochip technology.
read more » - 14.12.06
SIRS-Lab successfully raises EURO 10M new equity capital to introduce its first sepsis diagnostic tests to the market
SIRS-Lab, the innovation leader in molecular diagnostics for life threatening infections announced today that it has successfully raised EURO 10 million new equity capital led by Affentranger Associates alongside with bm-t Beteiligungsmanagement Thüringen and Swiss institutional investors. The company will use the funds to bring new molecular diagnostics to the market to enable fast identification and simple monitoring of sepsis often a deadly disease.
read more »